产品名称

Vercirnon - GSK-1605786 | CCX282-B | Traficet-EN

产品货号

Axon 2685 CAS [698394-73-9] MF C22H21ClN2O4SMW 444.93 Purity: 100% Soluble in DMSO Description Vercirnon is an orally bioavailable selective antagonist of the CCR9 chemokine receptor (IC50 values 5.4 nM and 3.4 nM for CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells, respectively). Based on studies of the crystal structure, vercirnon binds to the intracellular side of the receptor, exerting allosteric antagonism and preventing G-protein coupling. Vercirnon was developed for treatment of inflammatory bowel disease, including Crohn's disease and celiac disease. KEYWORDS: Vercirnon | supplier | CCR9 antagonist | GSK-1605786 | CCX282-B | Traficet-EN | GSK1605786 | GSK 1605786 | CCX282B | CCX282 B | Traficet EN | CAS [698394-73-9] | Chemokine | Chemokine | Antagonist | Receptors | Coeliac disease | Crohn's disease | Coeliac | Crohn

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

Vercirnon - GSK-1605786 | CCX282-B | Traficet-EN

Based on 22 reference(s) in Google Scholar 8 10 22

Axon 2685

CAS [698394-73-9]

MF C22H21ClN2O4S
MW 444.93

Purity: 100%
Soluble in DMSO

Vercirnon

Description

Vercirnon is an orally bioavailable selective antagonist of the CCR9 chemokine receptor (IC50 values 5.4 nM and 3.4 nM for CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells, respectively). Based on studies of the crystal structure, vercirnon binds to the intracellular side of the receptor, exerting allosteric antagonism and preventing G-protein coupling. Vercirnon was developed for treatment of inflammatory bowel disease, including Crohn's disease and celiac disease.

KEYWORDS: Vercirnon | supplier | CCR9 antagonist | GSK-1605786 | CCX282-B | Traficet-EN | GSK1605786 | GSK 1605786 | CCX282B | CCX282 B | Traficet EN | CAS [698394-73-9] | Chemokine | Chemokine | Antagonist | Receptors | Coeliac disease | Crohn's disease | Coeliac | Crohn

MJ Walters et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2010 Oct;335(1):61-9.

B Eksteen et al. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs. 2010 Jul;13(7):472-81.

C Oswald et al. Intracellular allosteric antagonism of the CCR9 receptor. Nature. 2016 Dec 15;540(7633):462-465.

Immunology Pain & Inflammation A1 Chemokine

CCR9 antagonist

Chemical name

4-(2-(4-Tert-butylphenylsulfonamido)-5-chlorobenzoyl)pyridine 1-oxide

Parent CAS No.

[698394-73-9]

产品资料